Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis.

CONCLUSION: In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo. Further clinical trials are required to demonstrate any cognitive benefits of immunotherapies in mild-to-moderate AD. PMID: 30904037 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30904037?dopt=Abstract

Source: Clinical and Investigative Medicine - March 22, 2019 Category: Biomedical Science Authors: Foroutan N, Hopkins RB, Tarride JE, Florez ID, Levine M Tags: Clin Invest Med Source Type: research